Przegląd Gastroenterologiczny
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

without publication fees
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:

Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors

Krystian Adrych
1
,
Jarosław Daniluk
2
,
Ewa Nowakowska-Duława
3
,
Andrzej Białek
4
,
Grażyna M. Rydzewska
5, 6

  1. Department of Gastroenterology and Hepatology, Medical University of Gdansk, Poland
  2. Department of Gastroenterology and Internal Diseases, Medical University of Bialystok, Poland
  3. Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland
  4. Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland
  5. Department of Internal Medicine and Gastroenterology and Subdivision for Treatment of Inflammatory Bowel Diseases, the National Medical Institute of the Ministry of Internal Affairs and Administration, Warsaw, Poland
  6. Department of Gastrointestinal Disease Prevention, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
Gastroenterology Rev
DOI: https://doi.org/10.5114/pg.2025.156465
Data publikacji online: 2025/11/24
Plik artykułu:
- Position statement.pdf  [0.29 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008; 22: 209-24.
2. Hearnshaw SA, Logan RFA, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-35.
3. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-46.
4. Orpen-Palmer J, Stanley AJ. Update on the management of upper gastrointestinal bleeding. BMJ Med 2022; 1: e000202.
5. Triantafyllou K, Gkolfakis P, Gralnek IM, et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 850-68.
6. Oakland K, Guy R, Uberoi R, et al. Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. Gut 2018; 67: 654-62.
7. Oakland K, Chadwick G, East JE, et al. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. Gut 2019; 68: 776-89.
8. Saydam Ş, Molnar M, Vora P. The global epidemiology of upper and lower gastrointestinal bleeding in general population: a systematic review. World J Gastrointest Surg 2023; 15: 723-39.
9. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012; 66: 53-63.
10. Suwa M, Nohara Y, Morii I, Kino M. Safety and efficacy re-evaluation of edoxaban and rivaroxaban dosing with plasma concentration monitoring in non-valvular atrial fibrillation: with observations of on-label and off-label dosing. Circ Rep 2023; 5: 80-9.
11. Coleman CI, Dobesh PP, Danese S, et al. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future Cardiol 2021; 17: 127-35.
12. Martin AC, Benamouzig R, Gouin-Thibault I, Schmidt J. Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion. Am J Cardiovasc Drugs 2023; 23: 407-18.
13. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
14. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635-41.
15. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial. J Am Coll Cardiol 2015; 66: 2271-81.
16. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015; 169: 25-30.
17. Miller CS, Dorreen A, Martel M, et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1674-83.e3.
18. Sengupta N, Tapper EB, Patwardhan VR, et al. Risk factors for adverse outcomes in patients hospitalized with lower gastrointestinal bleeding. Mayo Clin Proc 2015; 90: 1021-9.
19. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124: 111-4.
20. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Haemostasis, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
21. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy 2021; 53: 300-32.
22. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-21.
23. Oakland K, Jairath V, Uberoi R, et al. Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 635-43.
24. Nagata N, Sakurai T, Moriyasu S, et al. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. PLoS One 2017; 12: e0183423.
25. Dager WE, Banares L. Reversing the anticoagulation effects of dabigatran. Hosp Pract 2017; 45: 29-38.
26. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol 2022; 117: 542-58.
27. Piran S, Khatib R, Schulman S, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv 2019; 3: 158-67.
28. Rahman R, Nguyen DL, Sohail U, et al. Pre-endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-analysis and systematic review. Ann Gastroenterol 2016; 29: 312-7.
29. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2: 394-7.
30. Bradshaw PG, Keegan SP, Droege ME, et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy 2022; 42: 780-91.
31. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-20.
32. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377: 431-41.
33. Sengupta N, Feuerstein JD, Jairath V, et al. Management of patients with acute lower gastrointestinal bleeding: an updated ACG Guideline. Am J Gastroenterol 2023; 118: 208-31.
34. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23: 1612-76.
35. Milling TJ, Middeldorp S, Xu L, et al. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors.
36. Circulation 2023; 147: 1026-38.
37. (2013) Portola gets FDA breakthrough therapy status for andexanet alfa. Available at: https://www.pharmaceutical-technology.com/uncategorized/newsportola-gets-fda-breakthrough-therapy-status-for-andexanet-alfa/.
38. FDA, (2018) Summary Basis for Regulatory Action. Available at: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/May-3--2018-Summary-Basis-for-Regulatory-Action---ANDEXXA.pdf .
39. EMA, 2019, Ondexxya (andexanet alfa). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya .
40. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-24.
41. Brown CS, Scott RA, Sridharan M, Rabinstein AA. Real-world utilization of andexanet alfa. Am J Emerg Med 2020; 38: 810-4.
42. Giovino A, Shomo E, Busey KV, et al. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg 2020; 195: 106070.
43. Barra ME, Das AS, Hayes BD, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost 2020; 18: 1637-47.
44. Vestal ML, Hodulik K, Mando-Vandrick J, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis 2022; 53: 167-75.
45. Sutton SS, Magagnoli J, Cummings TH, et al. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis 2023; 56: 137-46.
46. Dobesh PP, Fermann GJ, Christoph MF, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Res Pract Thromb Haemost 2023; 7: 102192.
47. Cohen AT, Lewis M, Connor A, et al. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. J Am Coll Emerg Physicians Open 2022; 3: e12655.
48. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 2020; 76: 594-622.
49. Raport komunikacyjny polskich ekspertów z neurologii, kardiologii, hematologii, medycyny ratunkowej i gastroenterologii. Nowe możliwości terapeutyczne w krwotokach zagrażających życiu występujących u osób w trakcie leczenia ksabanami. Grant AstraZeneca, Kraków 2024.
50. Kubica J, Adamski P, Gajda R, et al. Andexanet alfa - recommendations for clinical use. Multidisciplinary experts’ standpoint. Cardiol J 2023; 30: 502-5.
51. Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut 2021; 70: 1611-28.
52. Gralnek IM, Duboc MC, Garcia-Pagan JC, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2022; 54: 1094-120.
53. Kazimierczyk E, Dąbrowska M, Gierlotka M, et al. The use of andexanet alpha in the Polish setting: an interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society. Kardiol Pol 2024; 82: 123-39.
54. AaSoPC, 30 European Medicines Agency. September 12, 2020: https://www.ema.europa.eu/en/documents/product-information/ondexxya-epar-product-information_en.pdf.
55. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380: 1326-35.
56. Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 2024; 390: 1745-55.
57. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-51.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Mednauka Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2025 Termedia Sp. z o.o.
Developed by Bentus.